Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials

Etravirine is a recently approved nonnucleoside reverse transcriptase inhibitor. The ability of etravirine to limit the emergence of resistance to protease inhibitors, and specifically to darunavir, was investigated in the subset of treatment-experienced patients with virologic rebound in the phase...

Ausführliche Beschreibung